TXN and prostate cancer: The binding activity of the nanodevice to the epithelial cells as well as the stroma of BPH was undetectable suggesting that the targeted thioredoxin proteins are not present in nonreactive stroma, and that the nanodevice is specifically binding to reactive stroma present in prostate cancer.